| NCT ID | NCT07490171 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Methodist Health System |
| Condition | Trauma |
| Study Type | OBSERVATIONAL |
| Enrollment | 100 participants |
| Start Date | 2026-02 |
| Primary Completion | 2027-02 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 100 participants in total. It began in 2026-02 with a primary completion date of 2027-02.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This retrospective data repository will serve as a means to aggregate and analyze order of pre-hospital care (intubation, medication, etc) as it relates to Traumatic cardiac arrest.
Eligibility Criteria
Inclusion Criteria: ≥18 years old Included in the MDMC Trauma Registry Cardiac arrest in pre-hospital setting or trauma bay Exclusion Criteria: \<18 years old Prisoners, pregnant persons, or other protected population
Contact & Investigator
Andrew Karpisek, MD
PRINCIPAL INVESTIGATOR
Methodist Health System
Frequently Asked Questions
Who can join the NCT07490171 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Trauma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07490171 currently recruiting?
Yes, NCT07490171 is actively recruiting participants. Contact the research team at ClinicalResearch@mhd.com for enrollment information.
Where is the NCT07490171 trial being conducted?
This trial is being conducted at Dallas, United States.
Who is sponsoring the NCT07490171 clinical trial?
NCT07490171 is sponsored by Methodist Health System. The principal investigator is Andrew Karpisek, MD at Methodist Health System. The trial plans to enroll 100 participants.